Abstract
This study aimed to investigate the effect of multimodality treatment of advanced paediatric hepatoblastoma (HB) and the factors affecting prognosis. A total of 35 children underwent multimodality treatments consisting of chemotherapy, surgery, interventional therapy, and autologous peripheral blood stem cell transplantation. The patients were followed up every month. Serum AFP levels in 33 out of 35 patients in this study were significantly increased (P = 0.0002). According to the statistical scatter plot, the values of serum AFP on the 25th, 50th, and 75th percentages were 1,210, 1,210 and 28,318 ng/dl, respectively. Of the 35 cases, 21 were stage IV. 18 cases were treated with systemic chemotherapy before surgery, and 3 cases with locally interventional chemotherapy before surgery. Statistical analysis showed that the preferred interventional treatment affected prognosis, and that there was a statistically significant difference (P = 0.024). Some 33 patients completed the follow-up, of which 17 were in complete remission (CR), 5 were in partial remission (PR), 1 became disease progressive (DP) , and 10 died. The remission and overall survival rates were 66.7% (22/33) and 69.7% (23/33), respectively. Patients with the mixed HB phenotypes had worse prognoses than the epithelial phenotype (P < 0.001), and patients in stage IV had a lower survival rate than those in stage III (P < 0.001). Multimodality treatment can effectively improve remission rate and prolong the survival of children with advanced HB. In addition, alpha-fetoprotein (AFP), a tumor marker of liver malignant tumors, HB pathological classification, and staging are highly useful in predicting prognosis.
Highlights
Hepatoblastoma (HB) is the most common malignant liver tumor in children, accounting for 50% of liver tumors and 1.3% of malignant tumors in children (Bulterys et al, 1999; Stocker, 2001; Zsíros et al, 2012)
This study aimed to investigate the effect of multimodality treatment of advanced paediatric hepatoblastoma (HB) and the factors affecting prognosis
A total of 35 children underwent multimodality treatments consisting of chemotherapy, surgery, interventional therapy, and autologous peripheral blood stem cell transplantation
Summary
Hepatoblastoma (HB) is the most common malignant liver tumor in children, accounting for 50% of liver tumors and 1.3% of malignant tumors in children (Bulterys et al, 1999; Stocker, 2001; Zsíros et al, 2012). In the 1970s, the main treatment of HB came in the form of a single surgery, with no chemotherapy after operation; at that time, the overall HB survival rate was only 20% to 30% (Evans et al, 1982). The main treatment methods include surgery, chemotherapy, liver transplantation, and local infusion chemotherapy (Czauderna et al, 2006; von Schweinitz, 2006; Gupta et al, 2011; Meyers and Otte, 2011; Perilongo et al, 2011). Our aim is to review the clinical efficacy and prognosis of HB, especially advanced HB, with chemotherapy and APBSCT, and to review the clinical efficacy of locally interventional chemotherapy before surgery, as well as to provide some clinical experience
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
